Benjamin Schlechter, MD, discusses the unmet needs and treatment gaps for patients with colorectal cancer.
Incorporating Immunotherapy Into the CRC Treatment Landscape
Botensilimab/balstilimab (BOT/BAL) synergistically activate and sustain immune attack, offering a promising new strategy for various cancers.
Benjamin Schlechter, MD, discusses the safety and efficacy findings from the C-800-01 phase 1 trial evaluating botensilimab and balstilimab in colorectal cancer.
Unpredictable FDA and funding woes delay crucial drug approvals, depriving thousands of patients access to vital treatments for diseases like colon cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Clears Pen Device for Interferon Therapy in Polycythemia Vera
2
FDA Rejects Edotreotide PET Imaging Kit Over Manufacturing Concerns
3
Deep Responses Support Push for CAR T-Cell Therapy in AL Amyloidosis
4
Phase 3 TRIDENT Trial Misses Survival End Point in Glioblastoma
5